Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.
131I-labeled monoclonal antibodies were used in therapeutic trials in two potentially useful clinical situations: disseminated melanoma (intravenously administered Fab fragments; 21 patients) and disseminated peritoneal adenocarcinomatosis (intraperitoneal injection of IgG; 5 patients). Acute toxicity observed is consistent with mild bone marrow suppression of acute radiation syndrome and the observed toxicity is dose related in a manner that conforms to the expected human response to total body irradiation. For single doses of both i.p. administered and intravenously administered 131I-labeled anti-tumor antibodies, 100 rad to red marrow, calculated by the absorbed dose fraction method (MIRD), appeared to be a threshold below which significant acute toxicity was unlikely.
Larson
S M
SM
Department of Nuclear Medicine, National Institutes of Health, Bethesda, MD 20892.
Raubitschek
A
A
Reynolds
J C
JC
Neumann
R D
RD
Hellstrom
K E
KE
Hellstrom
I
I
Colcher
D
D
Schlom
J
J
Glatstein
E
E
Carrasquillo
J A
JA
D000230:Adenocarcinoma / Q000532:radiotherapy / Q000556:secondary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001853:Bone Marrow / Q000528:radiation effects*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008545:Melanoma / Q000532:radiotherapy; D009369:Neoplasms / Q000532:radiotherapy*; D010534:Peritoneal Neoplasms / Q000532:radiotherapy / Q000556:secondary; D011878:Radiotherapy / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes